AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
Phase 3
Terminated
- Conditions
- Asthma
- Interventions
- Biological: BenralizumabBiological: Placebo
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13
- Registration Number
- NCT01947946
- Locations
- 🇷🇺
Research Site, Vladikavkaz, Russian Federation
Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor
Completed
- Conditions
- Non-Small-Cell Lung Cancer
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 346
- Registration Number
- NCT01947868
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5000
- Registration Number
- NCT01944618
- Locations
- 🇦🇺
Local Institution, Clayton, Victoria, Australia
Specific Clinical Experience Investigation for Long-term Use of Bydureon.
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1137
- Registration Number
- NCT01940770
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 269
- Registration Number
- NCT01938612
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT01937338
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Phase 3
Active, not recruiting
- Conditions
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
- Interventions
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 510
- Registration Number
- NCT01933932
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
Phase 1
Completed
- Conditions
- Solid Tumours
- Interventions
- Drug: [C14] selumetinib (oral)
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT01931761
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours
Phase 1
Completed
- Conditions
- Solid Tumours
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT01929603
- Locations
- 🇳🇱
Research Site, Maastricht, Netherlands
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914
Phase 1
Completed
- Conditions
- Gonococcal (GC) Infection
- Interventions
- Drug: Part ADrug: Part B
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2014-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT01929629
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States